Compare Enphase Energy Inc (ENPH) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enphase Energy Inc vs Sana Biotechnology Inc — how do they compare? Enphase Energy Inc trades at $40.85 (market cap $5.59B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Enphase Energy Inc is far larger — about 4.9× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.
| ENPH | SANA | |
|---|---|---|
Market Cap | $5.59B | $1.13B |
Sector | Technology | Health |
52-Week High | $72.33 | $5.92 |
52-Week Low | $26.12 | $2.68 |
Enterprise Value | $5.23B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $40.86, down 0.15% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings that matched estimates but missed revenue expectations, with revenue declining 19.6% year-over-year. Recent news highlights product expansion including IQ Battery 10C support for third-party systems and reinforced U.S. manufacturing commitments across residential, commercial and AI infrastructure segments.
While analyst consensus remains cautiously optimistic with a $45.37 price target, ENPH faces headwinds from cyclical residential solar demand and competitive pressures. The stock offers potential upside if the company can execute on its storage-led recovery strategy and capitalize on AI data center opportunities, though investors should monitor execution risks and market volatility in the solar sector.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
